Aerie Pharmaceuticals
AERI
AERI was delisted on the 18th of November, 2022.
155 hedge funds and large institutions have $712M invested in Aerie Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 55 increasing their positions, 54 reducing their positions, and 27 closing their positions.
2% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 54
0% more funds holding
Funds holding: 155 → 155 (0)
0% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 27
1% less capital invested
Capital invested by funds: $716M → $712M (-$4.29M)
56% less call options, than puts
Call options by funds: $572K | Put options by funds: $1.29M
83% less funds holding in top 10
Funds holding in top 10: 6 → 1 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair Investment Management
Chicago,
Illinois
|
+$20.3M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$19.9M |
| 3 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$17.5M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$11M |
| 5 |
Morgan Stanley
New York
|
+$7.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$83.2M |
| 2 |
DM
Deerfield Management
New York
|
-$30.1M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
-$8.71M |
| 4 |
First Manhattan
New York
|
-$7.81M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$6.84M |
AERI Hedge Fund Activity: Q2 2020 in Review
155 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q2 2020, worth a combined $712M — down 0.6% from $716M a quarter earlier.
Fund positioning in AERI was balanced in Q2 2020: 27 funds opened new positions, 27 closed out, 55 added to existing stakes and 54 trimmed.
The largest buyer was William Blair Investment Management, opening a new position worth an estimated $20.3M. The largest seller was Wellington Management Group, cutting an estimated $83.2M.
- 155 institutional investors held Aerie Pharmaceuticals (AERI) as of Q2 2020, unchanged from Q1 2020.
- Funds reported $712M of Aerie Pharmaceuticals stock for Q2 2020, down 0.6% quarter-over-quarter.
- 27 funds opened new Aerie Pharmaceuticals positions in Q2 2020 and 27 closed out, a net change of 0 holders.
- The largest Aerie Pharmaceuticals buyer in Q2 2020 was William Blair Investment Management, an estimated $20.3M added.
- The largest Aerie Pharmaceuticals seller in Q2 2020 was Wellington Management Group, an estimated $83.2M sold.
Based on aggregated 13F filings for Q2 2020.